ReviewFrontiers in molecular biosciences2026
Decoding protein signaling networks in microvascular angina: the multi-target biochemical actions of traditional Chinese medicine.
Review in Frontiers in molecular biosciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although angina pectoris is among the most common conditions in cardiology, a substantial proportion of symptomatic patients exhibit persistent ischemia without flow-limiting epicardial coronary artery disease-termed ANOCA (angina with nonobstructive coronary arteries). Accumulating evidence underscores coronary microvascular dysfunction as central to ANOCA's pathophysiology, involving molecular mechanisms such as endothelial dysfunction, oxidative stress, vascular inflammation, impaired vasodilation, microvascular remodeling, metabolic disturbance, and reduced coronary flow reserve. These interconnected pathways challenge the efficacy of single-target therapies. Traditional Chinese medicine (TCM), with its multi-target systems-based approach, offers a promising therapeutic model. Preclinical and clinical studies reveal that representative TCM formulas and bioactive compounds preserve endothelial integrity, suppress pro-inflammatory cytokines, attenuate oxidative injury, restore mitochondrial and metabolic homeostasis, stimulate angiogenesis, and improve myocardial perfusion. Such effects align with the molecular complexity of ANOCA, suggesting TCM could complement conventional cardiovascular treatments. This review synthesizes current understanding of coronary microvascular pathobiology, traces the evolution of microvascular-protective therapeutic concepts, and evaluates TCM's mechanistic and clinical evidence base. While findings highlight TCM's therapeutic potential, translational limitations persist-including heterogeneity in diagnostic criteria, variability in herbal formulations, methodological inconsistencies, and gaps in robust evidence. Integrating mechanistic, clinical, and translational data, this work delineates the scientific foundation, therapeutic promise, and future research directions for TCM in ANOCA-related coronary microcirculation disorders, advocating for standardized, mechanism-driven investigations to enable evidence-based integration into cardiovascular care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.